The Top 5 Biosimilars Articles for the Week of December 9
The Center for Biosimilars® recaps the top stories for the week of December 9, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 9, 2019.
Number 5: Increased spending on new oncology and autoimmune drugs was partially offset by a continued increase in the use of generics, according to a recent report from CMS.
Number 4: During this week’s 61st meeting of the American Society of Hematology, researchers reported on eculizumab, a prospective biosimilar, and a long-acting successor.
Number 3: Sanofi announced that it will stop research and development on diabetes drugs, but it will keep a proposed biosimilar of insulin aspart in its pipeline as a registration-phase molecule.
Number 2: An agreement on the United States—Mexico–Canada Agreement has been reached, and it excludes controversial terms for biologics.
Number 1: The FDA has approved Amgen’s infliximab biosimilar, Avsola, the fourth biosimilar infliximab and the 26th US biosimilar.
Finally, last week, our e-newsletter asked how great an impact you think subcutaneously administered biosimilar infliximab will have on clinical practice.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
